Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer

This trial is testing a combination of cadonilimab (an immunotherapy drug targeting PD-1 and CTLA-4), bevacizumab (an anti-angiogenic drug), and FOLFOX chemotherapy as a first-line treatment for patients with advanced colorectal cancer that has specific genetic features (MSS-type and RAS-mutated) — a group typically resistant to standard immunotherapy. **You may be eligible if...** - You are aged 18–75 with confirmed metastatic colorectal adenocarcinoma - Your tumor is MSS (microsatellite stable) and has a RAS mutation - You have not received any prior systemic treatment for your metastatic disease - You have at least one measurable tumor and are in good overall health (ECOG 0–1) **You may NOT be eligible if...** - Your tumor is MSI-H (high microsatellite instability) or RAS wild-type - You have had prior immunotherapy (checkpoint inhibitors) - You have another active cancer within the past 3 years (with some exceptions) - You have had prior chemotherapy within 3 weeks of starting the study Talk to your doctor to see if this trial is right for you.